Content area

|
|

Risici ved brug af selektive serotoningenoptagelseshæmmere til gravide

Forfatter(e)
Terje Martens1, Per Damkier2 & Poul Videbech3
1) Psykiatrisk Center Glostrup, Region Hovedstadens Psykiatri 2) Afdeling for Klinisk Biokemi og Farmakologi, Odense Universitetshospital 3) Center for Neuropsykiatrisk Depressionsforskning, Psykiatrisk Center Glostrup, Region Hovedstadens Psykiatri

Ugeskr Læger 2019;181:V06190338
Reference: 
Ugeskr Læger 2019;181:V06190338

Terje Martens, Per Damkier & Poul Videbech:

The risks of selective serotonin reuptake inhibitor intake in pregnancy

Ugeskr Læger 2019;181:V06190338

Depression in pregnancy is common and may have serious consequences for the mother and foetus when untreated.
In this review, we discuss selective serotonin reuptake inhibitor (SSRI) intake in pregnancy, which has been associated with increased risk of several unwanted events. However, the evidence indicating a causal relationship between the intake of SSRI in pregnancy and most investigated outcomes is of very low certainty. Confounding by indication likely accounts for most of the observed correlations. If, for any outcomes, an increased risk exists, the number needed to harm is high, and the clinical significance is unclear.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Frederik Winsløw | 22/01
2 kommentarer
af Helle Borgstrøm | 22/01
10 kommentarer
af Martin Lindhardt Nielsen | 22/01
1 Kommentar
af Kurt Håkonsson | 19/01
4 kommentarer
af Erik Kristensen | 17/01
20 kommentarer
af Thomas Michael Dan Aru | 17/01
4 kommentarer
af Claus Bo Svenningsen | 15/01
1 Kommentar